Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Two functional forms of corneal endothelial cell replacement therapies in a non-human primate model of corneal endothelial dysfunction
Author Affiliations & Notes
  • Gary S L Peh
    Singapore Eye Research Institute, Singapore, Singapore
    Duke-NUS Medical School, Singapore, Singapore
  • Belinda Tan
    Singapore Eye Research Institute, Singapore, Singapore
  • Dawn Neo
    Singapore Eye Research Institute, Singapore, Singapore
  • Xiao Yu Ng
    Singapore Eye Research Institute, Singapore, Singapore
  • Hon Shing Ong
    Singapore National Eye Centre, Singapore, Singapore, Singapore
    Singapore Eye Research Institute, Singapore, Singapore
  • Jodhbir S Mehta
    Singapore National Eye Centre, Singapore, Singapore, Singapore
    Singapore Eye Research Institute, Singapore, Singapore
  • Footnotes
    Commercial Relationships   Gary Peh None; Belinda Tan None; Dawn Neo None; Xiao Yu Ng None; Hon Shing Ong None; Jodhbir Mehta None
  • Footnotes
    Support  (NMRC-CSA: MOH000197 & NMRC-CSIRG: MOH-001232-00)
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4484. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gary S L Peh, Belinda Tan, Dawn Neo, Xiao Yu Ng, Hon Shing Ong, Jodhbir S Mehta; Two functional forms of corneal endothelial cell replacement therapies in a non-human primate model of corneal endothelial dysfunction. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4484.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study is to demonstrate the therapeutic outcome of two distinct preparations of functional primary corneal endothelial cells (CECs) for cell injection in a non-human primate (NHP) of corneal endothelial dysfunction.

Methods : Donor corneas unsuitable for transplantation were procured and processed either by (1) isolation and propagation to the second passage using a dual media cell expansion protocol as Group A cultured CECs, or by (2) utilizing a simple non-cultured endothelial cells (SNEC) harvesting methodology as Group B non-cultured CECs. Two species of NHP (rhesus and cynomolgus) were used in this study.

On the day of transplantation, the corneal endothelium of the macaque was first carefully scrapped. For Group A macaques, at least 6 x 105 of expanded CECs were injected into the anterior chamber. For Group B macaques, at least 1.5 X 105 of SNEC-harvested CECs were used in each injections. Rho-associated protein kinase inhibitor (ROCKi; AR-13503 - 5μM (ARVO-2023)) was supplemented in all procedures. Negative control animals received non-cellular sham injections. All animals were left in a proned, face-down position for a minimum of 3 hours.

Central corneal thickness (CCT) and corneal clarity were assessed weekly for at least 30 days, with some animals maintained for up to 4 months. End-point analysis included immunohistochemistry of human-specific nuclei (HuNu and STEM101) in the excised corneas of the macaques.

Results : Our results showed that both Group A macaques (receiving expanded CECs) and Group B macaques (receiving SNEC-harvested CECs ), had comparable CCT to that of the pre-operated cornea throughout the main time-points assessed. Corneas in both groups of animals remained clear for at least 30 days, and up to 4 months in animals assigned for long-term evaluation. Corneal endothelium of the excised macaque's corneas receiving cell injections were found to express human specific nuclei, suggesting that functionality was conferred by injected primary CECs in both Group A and Group B macaques. For negative control animals, CCT increased to over 1,000μm by the fourth day, and corneas were opaque throughout the assessment period.

Conclusions : This current study using NHP showed that both preparations of cadaveric donor-derived CECs are robust in yielding functional primary CECs for corneal endothelial cell injection therapy.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×